Format

Send to

Choose Destination
Enferm Infecc Microbiol Clin. 2013 Dec;31(10):672-84. doi: 10.1016/j.eimc.2013.02.001. Epub 2013 Mar 29.

[The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)].

[Article in Spanish]

Author information

1
Panel de Expertos del Grupo de estudio de Sida (GESIDA-SEIMC) y de la Secretaría del Plan Nacional sobre el Sida (SPNS); Unidad de Enfermedades Infecciosas, Hospital Universitario 1050 Reina Sofía-IMIBIC, Córdoba, España. Electronic address: ariveror@gmail.com.

Abstract

This consensus document was prepared by an expert panel of the Grupo de Estudio de Sida (GESIDA [Spanish AIDS Study Group]) and the Plan Nacional sobre el Sida (PNS [Spanish National AIDS Plan]). The document updates current guidelines on the treatment of tuberculosis (TB) in HIV-infected individuals contained in the guidelines on the treatment of opportunistic infections published by GESIDA and PNS in 2008. The document aims to facilitate the management and treatment of HIV-infected patients with TB in Spain, and includes specific sections and recommendations on the treatment of drug-sensitive TB, multidrug-resistant TB, and extensively drug-resistant TB, in this population. The consensus guidelines also make recommendations on the treatment of HIV-infected patients with TB in special situations, such as chronic liver disease, pregnancy, kidney failure, and transplantation. Recommendations are made on the timing and initial regimens of antiretroviral therapy in patients with TB, and on immune reconstitution syndrome in HIV-infected patients with TB who are receiving antiretroviral therapy. The document does not cover the diagnosis of TB, diagnosis/treatment of latent TB, or treatment of TB in children. The quality of the evidence was evaluated and the recommendations graded using the approach of the Grading of Recommendations Assessment, Development and Evaluation Working Group.

KEYWORDS:

Anti-retroviral treatment; Antituberculous therapy; Extensively drug-resistant tuberculosis; Fármacos antituberculosos; Human immunodeficiency virus; Multidrug-resistant tuberculosis; Tratamiento antirretroviral; Tuberculosis; Tuberculosis con resistencia extendida; Tuberculosis multirresistente; Virus de la inmunodeficiencia humana

PMID:
23541879
DOI:
10.1016/j.eimc.2013.02.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center